PER

0.00%

10.0¢ percheron therapeutics limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-89

First 89 Last

Share
Profile

Follow
BoomCrashOffera

720 Posts.

210

01/02/23

18:04

Post #: 66013114
Share

Originally posted by samfiodiving: ↑

Great News Today

Although it would appear that Anthony Fippis ,s trip to San fran was to no avail as far as investment @ market was concerned ( Failure to create interest @ Market from his recent trip )

Lets hope that behind the scenes he was able to put across to the investment world out there, that he spoke to that, should our Combo trial be succesful, could we look towards an initial onboarding of a fund to the tune of around $6 - $7 mil to take us into a 6 - 9 patient 6 month trial to see the effects of the combo therapy

This would be an initial investment wherby if the small number combo trial is a success then look towards that huge investment from them and backing us into the US market that i have gone on about forever

If i do not see something released within these next 6 - 8 weeks then personally and this is my own personal opinion i will take his overseas trip as being a complete failure, and like he did back in 2011 when he tried to advance 1101 for cancer

As in

Afandin has advised ANP that it has made significant progress in attracting interest in the further development of ATL1101 and is currently in discussions with a number of corporate and investor groups, some of which are currently undertaking due diligence on ATL1101.

THEN SOME 6 MONTHS later after 1 year the agreement was terminated because funds could not be raised

We were informed the market was tough out there

So As was mentioned unlike the above where his efforts had to be reported to market, because he is now a member of ANP as mentioned earlier his discussions and findings will be kept within the inner sanctum we wont know how he went in San Fran

So for me 6 -8 weeks should be long enough to see a major Ann of intent to move this into human trials with investment backing

If he was succesful in San Fran Todays Ann should trigger both sides to get these negotiations underway and plans for clinical trial in motion

That is my run down like i said, the pipe line thus far

Has never let me down.

Its now down to Anthony to deliver on these results,

For once the path forwards has been taken of Marks shoulders

Is he the right man for the Job, well you have my time line

SEE HOW HE GOES

Expand

Hi Sam,

Forgive me if I missed it being mentioned on HC but just noticed Gil Price resigning as CEO of NeuroBo on Jan 18th.

ANP Price at posting: 8.8¢ Sentiment: Hold Disclosure: Held
5 Upvote

1 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

The market's shrugged at China's stimulus measures all year. Why is this one different?

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

There are more pages in this discussion • 34 more messages in this thread...

First 89 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 10.0¢		Change 0.000(0.00%)		Mkt cap ! $90.15M

Open	High	Low	Value	Volume
10.5¢	10.5¢	10.0¢	$47.27K	463.5K

Buyers (Bids)

No.	Vol.	Price($)
3	319942	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
10.5¢	86442	3

View Market Depth

No.	Vol.	Price($)
3	319942	0.100
3	113179	0.099
1	13000	0.098
2	130927	0.097
1	10004	0.096

Price($)	Vol.	No.
0.105	86442	3
0.110	290000	4
0.115	601850	5
0.120	275642	8
0.125	65000	2

Last trade - 16.10pm 27/09/2024 (20 minute delay)

PER (ASX) Chart

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-89

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Zeta Resources seeks to resolve the Panoramic takeover story

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-89

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Zeta Resources seeks to resolve the Panoramic takeover story

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News